AMEFX
Price
$24.33
Change
+$0.19 (+0.79%)
Updated
Dec 20 closing price
FIFAX
Price
$24.34
Change
+$0.19 (+0.79%)
Updated
Dec 20 closing price
Ad is loading...

AMEFX vs FIFAX

Header iconAMEFX vs FIFAX Comparison
Open Charts AMEFX vs FIFAXBanner chart's image
American Funds Income Fund of Amer F2
Price$24.33
Change+$0.19 (+0.79%)
VolumeN/A
CapitalizationN/A
American Funds Income Fund of Amer F3
Price$24.34
Change+$0.19 (+0.79%)
VolumeN/A
CapitalizationN/A
AMEFX vs FIFAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AMEFX vs. FIFAX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMEFX is a Buy and FIFAX is a Buy.

FUNDAMENTALS
Fundamentals
AMEFX (124B) and FIFAX (124B) have equal amount of cash in the bank . FIFAX (3.83) and AMEFX (3.73) have matching dividends . AMEFX was incepted earlier than FIFAX: AMEFX (16 years) vs FIFAX (8 years). AMEFX (40.00) and FIFAX (40.00) have comparable annual turnover. AMEFX has a lower initial minimum investment than FIFAX: AMEFX (250) vs FIFAX (1000000). FIFAX (9.42) and AMEFX (9.31) have marching annual gain over last year. FIFAX (19.91) and AMEFX (19.48) have equivalent 5 years return.
AMEFXFIFAXAMEFX / FIFAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years8 years-
Gain YTD8.4258.53599%
Front LoadN/AN/A-
Min. Initial Investment25010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets124B124B100%
Annual Yield % from dividends3.733.8397%
Returns for 1 year9.319.4299%
Returns for 3 years5.355.5996%
Returns for 5 years19.4819.9198%
Returns for 10 years32.05N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PFG77.302.12
+2.82%
Principal Financial Group
HI29.820.75
+2.58%
Hillenbrand
CIO5.450.12
+2.25%
City Office Reit
BLRX0.20N/A
+0.50%
BioLineRx Ltd
PSTX9.450.04
+0.43%
Poseida Therapeutics